Current smokers had significantly lower numbers of PD-L1-positive cells in the tumor core and tumor margins compared with never and former smokers [11], which is consistent with data that patients with smoking-high HNSCC have a lower response rate when given anti-PD-1 checkpoint inhibitors compared with smoking-low HNSCC [38]. This evidence concerns the gene PDCD1 and neoplasm.